Trends in Genetics
ReviewThe Epigenetic Regulator SMCHD1 in Development and Disease
Section snippets
FSHD
FSHD is a late-onset, progressive, muscular dystrophy which first presents in the muscles of the upper extremities and follows a descending progression. In severe cases FSHD can leave patients wheelchair-bound (reviewed in [6]). FSHD is the third most common neuromuscular condition and has been estimated to affect up to 1 in 8000 people worldwide [7]. Although landmark findings have advanced our understanding of the genetic and molecular basis for FSHD in the past decade, treatment for FSHD
BAMS
BAMS is the congenital absence of the nose and a reduction in eye size, often accompanied by a series of other malformations 17, 18. BAMS was formally described by Bosma in 1981 who observed the above symptoms in two unrelated boys with healthy parents [18]. A rare condition, it has since been reported in only 50 patients worldwide. Arhinia poses problems for affected individuals from birth, and extensive surgery is often required for BAMS patients from a young age to prevent structural
SMCHD1 As a Transcriptional Repressor
Much in the same way as human SMCHD1 functions at the D4Z4 array, SMCHD1 was first implicated in epigenetic control through its role in repeat-induced silencing of a murine multicopy GFP transgene for which expression is also variegated (Figure 2B) [24]. This strain was used in an N-ethyl-N-nitrosourea (ENU) mutagenesis screen to find novel epigenetic modifiers. The modifier of murine metastable epialleles dominant 1 (MommeD1) line generated in this screen harbours a nonsense mutation in Smchd1
SMCHD1 Is Crucial for XCI
In the absence of SMCHD1, both random XCI in the embryo and imprinted XCI in the placenta fail [22]. In the embryo, the early stages of XCI proceed normally, indicated by the accumulation of Xist long non-coding RNA (lncRNA) and H3K27me3 on the inactive X chromosome (Xi). However, there is a failure to properly establish or maintain silencing on the Xi, as indicated by the developmental window during which Smchd1MommeD1/MommeD1 female embryos die [22]. This observation is supported by in vitro
SMCHD1 Regulates Autosomal Monoallelic Gene Expression
Despite the prominent role of SMCHD1 in XCI, and the viability of Smchd1 null male mice on some genetic backgrounds, the ubiquitous expression of SMCHD1 in male and female cells suggests a broader role for SMCHD1 in regulating transcription 22, 24. Global expression analyses of cells and embryos derived from male Smchd1MommeD1/MommeD1 mice have shown that, in the absence of SMCHD1, autosomal monoallelic gene expression is perturbed at some imprinted clusters and at the clustered protocadherin
Molecular Mechanisms
Recent advances in our understanding of SMCHD1 structure and function, coupled with loss-of-function studies, have provided the first glimpses into the mechanisms underpinning SMCHD1 molecular function. Such an understanding would facilitate the development of therapeutic strategies to counter FSHD.
SMCHD1 is a non-canonical member of the SMC protein family, possessing a C-terminal SMC hinge domain and an N-terminal ATPase domain 4, 5. SMC proteins heterodimerise to form specific complexes
Model
SMCHD1 functions at loci that are subject to stable and heritable silencing, and these employ multiple epigenetic mechanisms to ensure silencing is maintained. When SMCHD1 is lost from these loci, there are widespread changes to the local chromatin environment, most markedly a dramatic loss of DNA methylation. At many SMCHD1 target enhancers and promoters, SMCHD1 and CTCF appear to have opposing roles. Indeed, while CTCF preferentially binds to unmethylated sequences, SMCHD1 has a preference
Concluding Remarks and Future Perspectives
SMCHD1 is an interesting case in that mutations that alter SMCHD1 function drive divergent human diseases that are characterised by distinct disease onset and affected tissues. While BAMS is a congenital disorder where treatment to inhibit SMCHD1 would not be of therapeutic benefit, FSHD can be diagnosed at the early stages of disease progression. The discovery of mutations that enhance the ATPase activity of SMCHD1 in BAMS patients raises the possibility that SMCHD1 has the potential to be
Acknowledgments
N.J. was supported by an Australian Postgraduate Award from the University of Melbourne. K.C. was supported by a Cancer Council Victoria Postdoctoral Fellowship. J.M.M. and M.E.B. were supported by National Health and Medical Research Council of Australia (NHMRC) R.D. Wright Fellowships (APP1105754 and APP1110206 respectively). The studies from laboratories of the authors reviewed herein were enabled by NHMRC Project grants 1045936 and 1098290, with additional support from NHMRC IRIISS 9000220
Glossary
- Chromatin relaxation
- the loss of heterochromatic chromatin modifications, such as DNA methylation, and histone H3 lysine 9 trimethylation (H3K9me3), and the simultaneous accumulation of euchromatic chromatin modifications, such as H3K4me3, which is often accompanied by transcriptional upregulation.
- DNA hypomethylation
- the loss of the methyl group from 5-methylcytosines.
- Enhancers
- regulatory sequences of DNA that can be bound by transcription factors and epigenetic modifiers and enhance the
References (67)
Genetic and epigenetic contributors to FSHD
Curr. Opin. Genet. Dev.
(2015)The DUX4 gene at the FSHD1A locus encodes a pro-apoptotic protein
Neuromuscul. Disord.
(2007)DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy
Dev. Cell
(2012)The FSHD2 gene SMCHD1 is a modifier of disease severity in families affected by FSHD1
Am. J. Hum. Genet.
(2013)Smchd1-dependent and -independent pathways determine developmental dynamics of CpG island methylation on the inactive X chromosome
Dev. Cell
(2012)Systematic discovery of Xist RNA binding proteins
Cell
(2015)Establishment of histone H3 methylation on the inactive X chromosome requires transient recruitment of Eed–Enx1 polycomb group complexes
Dev. Cell
(2003)X inactivation in the mouse embryo deficient for Dnmt1: distinct effect of hypomethylation on imprinted and random X inactivation
Dev. Biol.
(2000)Genomic imprinting disrupted by a maternal effect mutation in the Dnmt1 gene
Cell
(2001)- et al.
A striking organization of a large family of human neural cadherin-like cell adhesion genes
Cell
(1999)
Promoter choice determines splice site selection in protocadherin alpha and gamma pre-mRNA splicing
Mol. Cell.
Allelic gene regulation of Pcdh-alpha and Pcdh-gamma clusters involving both monoallelic and biallelic expression in single Purkinje cells
J. Biol. Chem.
Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2
Nat. Genet.
De novo mutations in SMCHD1 cause Bosma arhinia microphthalmia syndrome and abrogate nasal development
Nat. Genet.
SMCHD1 mutations associated with a rare muscular dystrophy can also cause isolated arhinia and Bosma arhinia microphthalmia syndrome
Nat. Genet.
The hinge domain of the epigenetic repressor Smchd1 adopts an unconventional homodimeric configuration
Biochem. J.
The epigenetic regulator Smchd1 contains a functional GHKL-type ATPase domain
Biochem. J.
Population-based incidence and prevalence of facioscapulohumeral dystrophy
Neurology
Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene
PLoS Genet.
Correlation analysis of clinical parameters with epigenetic modifications in the DUX4 promoter in FSHD
Epigenetics
Specific loss of histone H3 lysine 9 trimethylation and HP1gamma/cohesin binding at D4Z4 repeats is associated with facioscapulohumeral dystrophy (FSHD)
PLoS Genet.
Inter-individual differences in CpG methylation at D4Z4 correlate with clinical variability in FSHD1 and FSHD2
Hum. Mol. Genet.
Facioscapulohumeral muscular dystrophy is uniquely associated with one of the two variants of the 4q subtelomere
Nat. Genet.
Chromosome 4q DNA rearrangements associated with facioscapulohumeral muscular dystrophy
Nat. Genet.
Bosma arhinia microphthalmia syndrome: clinical report and review of the literature
Am. J. Med. Genet. Part A
Hypoplasia of the nose and eyes, hyposmia, hypogeusia, and hypogonadotrophic hypogonadism in two males
J. Craniofac. Genet. Dev. Biol.
Bosma arhinia microphthalmia syndrome
Am. J. Med. Genet. Part A
Vertical facial distraction in the treatment of arhinia
Plast. Reconstr. Surg.
Congenital arhinia: molecular-genetic analysis of five patients
Am. J. Med. Genet.
SmcHD1, containing a structural-maintenance-of-chromosomes hinge domain, has a critical role in X inactivation
Nat. Genet.
Diagnosis by sequencing: correction of misdiagnosis from FSHD2 to LGMD2A by whole-exome analysis
Eur. J. Hum. Genet.
An N-ethyl-N-nitrosourea screen for genes involved in variegation in the mouse
Proc. Natl. Acad. Sci. U. S. A.
Setdb1-mediated H3K9 methylation is enriched on the inactive X and plays a role in its epigenetic silencing
Epigenet. Chromatin
Cited by (43)
Epigenetic modifier SMCHD1 maintains a normal pool of long-term hematopoietic stem cells
2022, iScienceCitation Excerpt :In FSHD, heterozygous loss-of-function mutation of SMCHD1 results in relaxation of repressive chromatin structures at the D4Z4 macrosatellite repeat, leading to aberrant, variegated expression of the myotoxic gene DUX4 in skeletal muscle (Jansz et al., 2017; Lemmers et al., 2012). In BAMS, pathogenic SMCHD1 missense mutations fall exclusively within its extended ATPase domain; however, reports differ as to whether these variants lead to a loss or gain of SMCHD1 function (Gordon et al., 2017; Gurzau et al., 2018; Jansz et al., 2017; Lemmers et al., 2019; Shaw et al., 2017). Mechanistically, SMCHD1 works by maintaining long-range repressive chromatin structures; in the case of the inactive X chromosome (Xi), ablation of SMCHD1 leads to a strengthening of short-range interactions, altering the Xi architecture such that it adopts a structure more reminiscent of its active counterpart (Gdula et al., 2019; Jansz et al., 2018; Wang et al., 2018).
Analysis of Genome Architecture during SCNT Reveals a Role of Cohesin in Impeding Minor ZGA
2020, Molecular CellCitation Excerpt :Notably, a recent study revealed that the knockdown of Smchd1 (a non-canonical cohesin) in mouse zygote also results in overexpression of Zscan4 in 2-cell embryos (Ruebel et al., 2019). SMCHD1 is known to repress inactive X chromosome and a limited set of autosomal gene clusters that often reside in micro-heterochromatin (Jansz et al., 2017). In human somatic cells, mutations of Smchd1 cause relaxation of the D4Z4 macrosatellite array and the derepression of the embedded DUX4 gene, leading to facioscapulohumeral dystrophy (FSHD), a facial and upper-extremity muscle disease (Jansz et al., 2017).
A New Role for SMCHD1 in Life's Master Switch and Beyond
2019, Trends in GeneticsCitation Excerpt :Dux and Zscan4 mRNAs peak in expression at the early two-cell stage and are rapidly downregulated between 3 and 9 h after cleavage (Figure 1) [1]. ZSCAN4 nuclear protein staining also declines by 9 h post-cleavage (Figure 1) [1], indicating that the temporal regulation of SMCHD1 is consistent with a possible role in repressing DUX expression and EGA1 in two-cell embryos; also consistent with this, SMCHD1 represses DUX in somatic tissues [3]. The contribution of SMCHD1 in controlling EGA1 was tested in small interfering (si)RNA knockdown studies using siRNA microinjection at the one-cell stage [1].
Non-coding autoimmune risk variant defines role for ICOS in T peripheral helper cell development
2024, Nature CommunicationsSMCHD1 has separable roles in chromatin architecture and gene silencing that could be targeted in disease
2023, Nature Communications